View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsEvolva Holding 과거 순이익 실적과거 기준 점검 0/6Evolva Holding 의 수입은 연평균 -30.8%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 3%의 비율로 증가했습니다. 매출은 연평균 0.6%의 비율로 증가해 왔습니다.핵심 정보-30.76%순이익 성장률-14.93%주당순이익(EPS) 성장률Chemicals 산업 성장률4.35%매출 성장률0.64%자기자본이익률-1,822.84%순이익률-2,434.99%최근 순이익 업데이트31 Dec 2023최근 과거 실적 업데이트공시 • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024모든 업데이트 보기Recent updates공시 • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024공시 • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.공시 • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.공시 • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.공시 • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).New Risk • Nov 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).New Risk • Sep 29New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).공시 • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.공시 • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.Board Change • Jun 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Andreas Pfluger was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Evolva Holding가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BATS-CHIXE:EVEZ 매출, 비용 및 순이익 (CHF Millions)날짜매출순이익일반관리비연구개발비31 Dec 234-1014030 Sep 238-987430 Jun 2312-9410831 Mar 2314-6910931 Dec 2216-4311930 Sep 2214-44111030 Jun 2212-45121231 Mar 2211-43111231 Dec 2110-41101330 Sep 2110-41101330 Jun 2110-4291231 Mar 219-3691331 Dec 208-3091430 Sep 208-27101430 Jun 209-25111431 Mar 2010-23111431 Dec 1912-22121430 Sep 1912-23121530 Jun 1911-25131631 Mar 1910-27141731 Dec 189-29141930 Sep 188-31162830 Jun 187-33173831 Mar 187-36183331 Dec 177-39192830 Sep 178-38181430 Jun 1710-3717031 Mar 1710-3716031 Dec 1610-3615030 Sep 169-3514030 Jun 169-3413031 Mar 1611-3313031 Dec 1513-3212030 Sep 1514-3012030 Jun 1514-2811031 Mar 1512-2510031 Dec 1411-219030 Sep 1410-199030 Jun 1410-188031 Mar 149-178031 Dec 139-168030 Sep 138-157030 Jun 137-1460양질의 수익: EVEZ 은(는) 현재 수익성이 없습니다.이익 마진 증가: EVEZ는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: EVEZ은 수익성이 없으며 지난 5년 동안 손실이 연평균 30.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 EVEZ의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: EVEZ은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(-59.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: EVEZ는 현재 수익성이 없으므로 자본 수익률이 음수(-1822.84%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/26 12:02종가2024/04/24 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Evolva Holding SA는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sebastian BrayBerenbergSara WelfordEdison Investment ResearchMartin VoegtliResearch Partners AG1명의 분석가 더 보기
공시 • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024
공시 • Jul 16+ 1 more updateEvolva Holding SA to Report Fiscal Year 2023 Results on Oct 31, 2024Evolva Holding SA announced that they will report fiscal year 2023 results on Oct 31, 2024
공시 • Mar 07Evolva Holding SA, Annual General Meeting, Apr 12, 2024Evolva Holding SA, Annual General Meeting, Apr 12, 2024.
공시 • Feb 02Evolva Holding SA ADR - Sponsored to Be Deleted from OTC EquityEvolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated.
공시 • Dec 29Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss ExchangeLallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange.
공시 • Nov 23Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million.Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed.
New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years).
New Risk • Nov 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m).
New Risk • Sep 29New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m).
공시 • Sep 07Evolva Receives Approval for Veri-Te Resveratrol in ThailandEvolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region.
공시 • Jul 25Evolva Receives FDA Approval for Veri-teTM Resveratrol in TaiwanEvolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region.
Board Change • Jun 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Andreas Pfluger was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.